Compare Baxter International Inc (BAX) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Thomson Reuters Corp — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.36B), while Thomson Reuters Corp trades at $104.52 (market cap $45.08B). The key difference: Thomson Reuters Corp is far larger — about 3.1× Baxter International Inc's market cap, and Thomson Reuters Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| BAX | TRI | |
|---|---|---|
Market Cap | $14.36B | $45.08B |
Sector | Health | Industrials |
52-Week High | $28.35 | $178.77 |
52-Week Low | $15.80 | $76.55 |
Enterprise Value | $21.88B | $47.69B |
Dividend Yield | 0.14% | 2.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.
The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.
Thomson Reuters (TRI) trades at $101.83, up 1.68% today, near the consensus price target of $102.33. The stock shows strong technical momentum with bullish moving averages and support at $99. Fundamentally, TRI delivered Q2 2026 earnings beat ($0.99 vs. $0.96 expected) with 8% organic revenue growth, while maintaining robust profitability margins (21.22% net income margin). Recent news highlights AI-driven product momentum and raised full-year revenue guidance.
Outlook remains positive with analyst consensus favoring Buy (51.85%) and 29.8% upside potential to high target of $124. Key risks include execution on AI transition and competitive pressures in legal/tax software markets. The company's recurring revenue model (82% of total) and dividend payments provide stability amid growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
